罗斯手术与人工瓣膜及同种异体主动脉瓣置换术的系统综述与荟萃分析
该系统综述与荟萃分析纳入13项观察性研究和2项随机对照试验(n=5346),比较罗斯手术与常规主动脉瓣置换术。观察性数据和随机对照试验数据均提示罗斯手术与晚期死亡率降低相关,但证据质量极低;随机对照试验中罗斯手术的全因再干预显著减少;术后30天内死亡率无差异。作者认为需进一步开展高质量随机研究。
要点
- 罗斯手术与常规主动脉瓣置换术相比,观察性数据(平均随访2.6年,RR 0.56,95%CI 0.38-0.84,I²=58%,极低质量)和随机对照试验数据(平均随访8.8年,RR 0.33,95%CI 0.11-0.96,I²=66%,极低质量)均提示晚期死亡率降低。
- 术后30天内死亡率两组无差异。
- 全因再干预在队列研究中两组相似(RR 1.41,95%CI 0.89-2.24,I²=55%,极低质量),在随机对照试验中罗斯手术显著减少(RR 0.41,95%CI 0.22-0.78,I²=68%,高质量)。
核心结论
- 观察性数据(存在残余混杂)和随机对照试验数据提示,与常规主动脉瓣置换术相比,罗斯手术具有晚期生存获益,且再干预风险未增加。
- 考虑到现有证据质量和有限的随访时间,需要进一步开展高质量随机研究以强化这些发现。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane CENTRAL,纳入评估成人患者罗斯手术与任何常规主动脉瓣置换术比较的研究。
- 共纳入13项观察性研究和2项随机对照试验(n=5346)。
- 采用ROBINS-I和Cochrane工具评估偏倚风险,采用GRADE框架评估证据质量,使用随机效应和固定效应模型合并数据。
- PROSPERO注册号:CRD42016052512。
主要发现
- 观察性数据中,罗斯手术与晚期死亡率降低相关(平均随访2.6年,RR 0.56,95%CI 0.38-0.84,I²=58%,极低质量)。
- 随机对照试验中,罗斯手术的效应估计相似(平均随访8.8年,RR 0.33,95%CI 0.11-0.96,I²=66%,极低质量)。
- 术后30天内死亡率无差异。
- 全因再干预在队列研究中两组相似(RR 1.41,95%CI 0.89-2.24,I²=55%,极低质量),在随机对照试验中罗斯手术显著减少(RR 0.41,95%CI 0.22-0.78,I²=68%,高质量)。
- 无观察性研究被评为低偏倚风险。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 观察性数据存在残余混杂。
- 无观察性研究被评为低偏倚风险。
- 现有证据质量低(观察性数据和随机对照试验中晚期死亡率结局均为极低质量)。
- 随访时间有限。
- 需要进一步开展高质量随机研究以强化这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Young adults undergoing aortic valve replacement (AVR) have decreased life expectancy compared to matched controls. The Ross procedure aims to improve valve lifespan while avoiding anticoagulation. We prepared a systematic review and meta-analysis to assess the Ross procedure compared to conventional AVR. METHODS: We searched MEDLINE, EMBASE and Cochrane CENTRAL for studies evaluating the Ross procedure versus any conventional AVR in adult patients. We performed screening, full-text assessment, risk of bias evaluation and data collection independently and in duplicate. We evaluated the risk of bias with the ROBINS-I and Cochrane tools and quality of evidence with the GRADE framework. We pooled data using the random- and fixed-effects models. RESULTS: Thirteen observational studies and 2 randomized controlled trials (RCTs) were identified (n = 5346). No observational study was rated as having low risk of bias. The Ross procedure was associated with decreased late mortality in observational and RCT data [mean length of follow-up 2.6 years, relative risk (RR) 0.56, 95% confidence interval (CI) 0.38-0.84, I2 = 58%, very low quality]. The RCT estimate of effect was similar (mean length of follow-up 8.8 years, RR 0.33, 95% CI 0.11-0.96, I2 = 66%, very low quality). No difference was observed in mortality <30 days after surgery. All-site reintervention was similar between groups in cohorts and significantly reduced by the Ross procedure in RCTs (RR 1.41, 95% CI 0.89-2.24, I2 = 55%, very low quality and RR 0.41, 95% CI 0.22-0.78, I2 = 68%, high quality, respectively). CONCLUSIONS: Observational data, with residual confounding, and RCT data suggest a late survival benefit with the Ross procedure with no increased risk of reintervention when compared to conventional AVR. Considering the quality of available evidence and limited follow-up, additional high-quality randomized studies are required to strengthen these findings. SYSTEMATIC REVIEW PROSPERO REGISTRATION: CRD42016052512.
引用
- McClure GR, Belley-Cote EP, Um K, et al. The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2019. PMID: 30084899. doi:10.1093/ejcts/ezy247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。